The WHO recommends the administration of sulfadoxine-pyrimethamine (SP) to all pregnant women living in areas of moderate (stable) to high malaria transmission during scheduled antenatal visits, beginning in the second trimester and continuing to delivery. Malaria parasites have lost sensitivity to SP in many endemic areas, prompting the investigation of alternatives that include azithromycin-based combination (ABC) therapies. Use of ABC therapies may also confer protection against curable sexually transmitted infections and reproductive tract infections (STIs/RTIs). The magnitude of protection at the population level would depend on the efficacy of the azithromycin-based regimen used and the underlying prevalence of curable STIs/RTIs among pregnant women who receive preventive treatment. This systematic review summarizes the efficacy data of azithromycin against curable STIs/RTIs.
The WHO recommends the administration of sulfadoxine-pyrimethamine (SP) to all pregnant women living in areas of moderate (stable) to high malaria transmission during scheduled antenatal visits, beginning in the second trimester and continuing to delivery. Malaria parasites have lost sensitivity to SP in many endemic areas, prompting the investigation of alternatives that include azithromycin-based combination (ABC) therapies. Use of ABC therapies may also confer protection against curable sexually transmitted infections and reproductive tract infections (STIs/RTIs). The magnitude of protection at the population level would depend on the efficacy of the azithromycin-based regimen used and the underlying prevalence of curable STIs/RTIs among pregnant women who receive preventive treatment. This systematic review summarizes the efficacy data of azithromycin against curable STIs/RTIs. The WHO recommends the administration of sulfadoxine-pyrimethamine (SP) to all pregnant women who live in areas of moderate (stable) to high malaria transmission during scheduled antenatal care (ANC) visits, beginning in the second trimester and continuing to delivery [1] . This intervention, known as intermittent preventive treatment of malaria in pregnancy (IPTp), is national policy in 36 countries worldwide, 35 of which are in sub-Saharan Africa [2] . The objective of IPTp-SP is to reduce the incidence of low birthweight and maternal anemia attributable to malaria. In recent years, however, malaria parasites have developed resistance to SP such that IPTp no longer reduces the incidence of low birthweight in some epidemiological settings, particularly in East Africa [3] . Evidence suggests that in areas where parasites express the 581G dhps mutation that is associated with SP resistance, the administration of IPTp-SP may even harm fetal growth [4] [5] [6] . Thus, the urgency to replace SP has never been greater and azithromycin-based combination (ABC) therapies are among leading candidates to do so.
Azithromycin is a slow-acting analog of erythromycin in the macrolide (azalide) class of drugs, which targets the ribosomal subunit of susceptible microorganisms and causes cellular death by inhibiting protein synthesis [7] . It has in vitro and in vivo antimalarial properties [8] and can be safely administered during pregnancy [9] . Two human challenge studies have published results of azithromycin monotherapy treatment against Plasmodium falciparum infection. The first study reported a protective effect of 40% (n = 10; 95% CI: 12-74%) among immunologically naïve patients who received 250 mg azithromycin daily for 2 weeks prior to inoculation and for 1 week more following exposure [10] . When the same regimen was used for one additional week post-inoculation, treatment efficacy was 100% (n = 10) [11] . Despite this finding, comparable results have not been replicated in endemic settings where patients often have mixed and multiple infections. However, in vitro evidence suggests that azithromycin may be combined with antimalarial partner drugs to prevent or to cure P. falciparum infection [12] , the malaria species most prevalent in sub-Saharan Africa and which uniquely adhere to the placenta of pregnant women. In addition to reducing the burden of malaria infection, ABC therapies may also protect against adverse birth outcomes attributable to curable sexually transmitted and reproductive tract infections (STIs/RTIs). This could offer considerable public health impact. A recent meta-analysis suggests that curable STIs/RTIs are as prevalent as malaria parasitemia, if not more so, among pregnant women who attend ANC facilities in subSaharan Africa [13] . Five curable STIs/RTIs -Treponema pallidum, Neisseria gonorrheae, Chlamydia trachomatis, Trichomonas vaginalis and bacterial vaginosis -are associated with adverse birth outcomes that include spontaneous abortion [14] [15] [16] [17] [18] , stillbirth [19] [20] [21] , intrauterine growth retardation [20, 22, 23] , premature rupture of membranes [24] [25] [26] , preterm birth [17, 22, 23, [26] [27] [28] [29] [30] [31] [32] [33] and low birthweight (TABLE 1) [20, 23, 24, 28, 29, [33] [34] [35] . This paper summarizes azithromycin efficacy and sensitivity against these curable STIs/RTIs and highlights important issues for policymakers to consider while determining the potential use of ABC therapies in IPTp.
Methodology
Between April and May 2013, PubMed, MEDLINE and EMBASE were searched using Medical Subject Headings and free-text terms for publications specific to the curable STIs/ RTIs noted above. With each query, the infection and causal organism were used together, for example, 'Syphilis' AND 'Treponema pallidum', and then combined with search terms 'azithromycin' OR 'macrolide'. Because the evidence base is limited with respect to azithromycin and some curable STIs/ RTIs, both 'azithromycin' and 'macrolide' were used as filters. We had particular interest in randomized clinical trials (RCTs) that compared azithromycin against the current first-line treatments for curable STIs/RTIs in pregnancy, noting that azithromycin is the WHO-recommended treatment for pregnant women infected with C. trachomatis. Searches were limited to the English language and strict inclusion and exclusion criteria were applied so as to narrow the number of papers retained. Reference lists were also reviewed for additional documents. Excluded records and full-text articles were in seven categories:
• 'Unrelated outcomes' were studies that reported nonclinical aspects of azithromycin use such as cost-effective analysis, noncommunicable diseases such as heart disease or pharmacological outcomes involving a route of administration that is not applicable to this review (e.g., intravenous); • 'Unrelated organisms' were papers dedicated to microbes that are not the focus of this review; • 'Not specific to STI/RTI' were articles on the subject of same genus of interest, for example, Chlamydia, but were not specific to the genital tract, for example, Chlamydia pneumoniae;
• 'Not related to azithromycin or close macrolide family' were papers that did not contain macrolides in their analysis or outcomes, but focused on different antimicrobials against the organisms in question; • 'Sequential observations from same source' involved surveillance reports from which most recent data set was used; • 'General discussion papers' contained information pertinent to the search, but failed to provide specific data for STIs/ RTIs.
• 'Contraindicated in pregnancy' were papers that reported outcomes of azithromycin combined with antimicrobial compounds that are considered unsafe in pregnancy.
A total of 122 articles met our primary inclusion criteria (FIGURE 1) .
Results

Treponema pallidum
In vivo evidence
The WHO recommends treating pregnant women with syphilis infection using 2.4 million units of benzanthine penicillin G (BPG) administered by intramuscular injection [36] . Thus, we summarize the results of the six clinical trials that reported outcomes among nonpregnant adults following treatment with BPG, azithromycin or a combination of BPG and azithromycin (TABLE 2) . The oldest data are from a trial in the USA (1993) (1994) (1995) (1996) (1997) in which individuals who discovered they had been exposed to infectious stage syphilis through sexual intercourse in the preceding 30 days were given either 1 g azithromycin (n = 40) or BPG (n = 23). Three months post-treatment, rapid plasma reagin (RPR) and fluorescent treponemal antibody absorption tests (FTA-ABS) were negative for all participants in both treatment groups [37] . Another trial in the USA during the same time period was designed to measure treatment outcomes in a population at high risk of contracting STIs/RTIs. Although diagnostic methods were not reported, the trial was suspended after two of the first 12 patients were provided 1 g azithromycin failed their test of cure while all 13 participants were cured using BPG (p = 0.18) [38] . A three-arm trial of early syphilis in the USA then compared treatment outcomes among patients given BPG, or 2 g azithromycin once or 2 g azithromycin two-times with 1 week in between doses. RPR and FTA-ABS testing showed that cure was achieved in 85.7% (n = 14; 95% CI: 60.0-95.7%) of patients given BPG, 94.1% (n = 17; 95% CI: 72.7-98.6%) among recipients of 2 g azithromycin once and 82.8% (n = 29; 95% CI: 65.3-92.3%) in participants who twice received 2 g azithromycin [39] .
In sub-Saharan Africa, three trials have investigated BPG versus azithromycin, the first being a community-randomized trial in Uganda (1994-1998) among nonpregnant adults with serological syphilis. Diagnosis and test of cure were based on toluidine red unheated serum tests (TRUSTs) and Treponema pallidum hemagglutination assays. Treatment efficacy varied across regimens depending on TRUST titers at enrolment. Among patients with initial titers <1:2, BPG cured 71.0% (n = 93; 95% CI: 61.0-79.2%) of cases compared with 58.5% [34] Elliott et al. On the pathway to better birth outcomes?
Review www.expert-reviews.com [40] . These results were followed by a trial carried out in Tanzania (2000) (2001) (2002) (2003) among patients who were recruited by screening high-risk populations. All 328 subjects had a titer of at least 1:8 on RPR test; 106 had baseline titers of >1:64, levels indicative of active syphilitic lesions. Confirmed by RPR test and T. pallidum particle agglutination assay, serological cure was observed in 97.5% (n = 163; 95% CI: 93.9-99.0%) of participants given 2 g azithromycin versus 95 .2% (n = 165; 95% CI: 90.7-97.5%) in the BPG group [41] .
The most recent study comparing the efficacy of azithromycin versus BPG is a multicenter trial (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) in Madagascar (n = 421) and North America (n = 94) among HIVnegative patients with early syphilis. Based on RPR testing, serological cure was reported in 77.6% of subjects given 2 g azithromycin (n = 232; 95% CI: 71.8-82.5%) and 78.5% (n = 237; 95% CI: 72.8-83.3%) in the BPG group. Nonserious adverse events were reported by 61.5% (n = 174; 95% CI: 55.7-67.0%) of individuals treated with 2 g azithromycin, most of whom had self-limiting gastrointestinal discomfort, whereas 46.1% (95% CI: 40.6-52.1%) of BPG recipients reported nonserious adverse events [42] .
In vitro evidence
Fourteen in vitro studies met our inclusion criteria, seven with isolates from low-risk populations (TABLE 3) and seven from highrisk or mixed-risk groups (TABLE 4) . A report from San Francisco in 2001 was the first to associate azithromycin treatment failure with A!G mutations at the 2,058 position of the 23S rRNA gene of T. pallidum [43] . Retrospective analysis of samples revealed that 4.0% (n = 25; 95% CI: 0.9-19.6%) of isolates had A!G mutations between 1999 and 2002. In 2003, the proportion of isolates with A!G mutations increased to 36.7% (n = 30; 95% CI: 21.9-54.6%) [44] ; by 2004, 56.1% (n = 66; 95% CI: 44.0-67.3%) had selected for resistance [43] . However, in Dublin, 88.2% (n = 17; 95% CI: 65.3-96.4%) of isolates already had A!G mutations by 2002 [44] .
Macrolide resistance is strongly associated with use by an individual in the previous year. Isolates from Seattle (2001 Seattle ( -2005 were two-times more likely to be resistant if patients had been treated with macrolides in the past 12 months (RR: 2.2; 95% CI: 1.1-4.4; p = 0.02) [45] . This relationship persisted over the decade. A2058G and A2059G mutations, which are associated with clinical failures of azithromycin, were found in 88.9% (n = 36; 95% CI: 74.6-95.5%) of isolates from 2001 to 2010 among patients exposed to macrolides in the preceding [301] .
Neisseria gonorrhoeae In vivo evidence
The WHO recommends treating pregnant women with Neisseria gonorrhoeae infection using 400 mg cefixime as a single dose or 125 mg ceftriaxone by intramuscular injection [50] . However, azithromycin has been used for the treatment of gonorrhea among nonpregnant adults during the past two decades. Eleven trials were identified through our review ( The pooled efficacy of azithromycin against N. gonorrhoea, estimated using random effects models [60] , was 97.0% (n = 539; 95% CI: 95.5-98.5%). This is slightly higher than 96.5% (n = 539; 95% CI: 94.3%-97.6%) reported in a 2010 review [61] that added numerators and divided the sum of denominators among the same nine trials. Such an approach does not account for heterogeneity across study populations and gives equal weight to all trials regardless of their precision. Regardless of pooling methods, it is unlikely that the same efficacy would be observed today using 1 g azithromycin in high-income countries following 25 years of cumulative drug pressure. However, the epidemiological context in sub-Saharan Africa is likely different where azithromycin use has been almost exclusively limited to trachoma eradication campaigns [62] .
We identified two RCTs that investigated the use of 2 g azithromycin among patients at STI clinics. The first was a multicenter trial in the USA (1991-1992) in which 98.9% (n = 374; 95% CI: 97.3-99.6%) of patients were cured [63] . A similar RCT in New Delhi (2005-2006) involved 42 participants; loss to follow-up was high, 52.4%, but all 22 subjects who returned for a test of cure had their N. gonorrhoeae infections cured [64] .
In vitro evidence
Over the past decade, in vitro studies have documented the loss of N. gonorrhoeae sensitivity to azithromycin. There are no standard breakpoints of minimum inhibitory concentrations (MICs) used to categorize N. gonorrhoeae resistance to azithromycin, but >1 mg/ml [65] and >2 mg/ml [66] have both been used. In this section, we summarize the key regional observations from 36 in vitro studies (TABLES 6 & 7) .
The Public Health Agency of Canada reported that 0.17% (n = 40,875; 95% CI: 0.001-0.002%) of N. gonorrhoeae Exposed to infectious syphilis [131] High-risk population On the pathway to better birth outcomes?
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Review Chico, Hack, Newport, Ngulube & Chandramohan Table 6 . Sensitivity testing of Neisseria gonorrhoeae isolates to azithromycin (cont.). 
90.1%
Isolates with reduced susceptibility also resistant to penicillin and tetracycline [168] Dillon et al. 
100%
One isolate reduced susceptibility [174] Ison et al. [67] . During the same 10-year period, the Centers for Disease Control and Prevention in the USA reported that 0.04% (n = 87.566; 95% CI: 0.03-0.06%) of N. gonorrhoeae isolates tested had MICs ‡8 mg/ml (including 25 with 8 mg/ml and 14 with 16 mg/ ml) [68] . This did not include five cases of azithromycinresistant N. gonorrhoeae found between August and October 2009 among men who have sex with men; three had MICs of 8 mg/ml and two had 16 mg/ml [69] . [70] . Collectively, azithromycin resistance was 13.0% (n = 8,373; 95% CI: 12.3-13.7%) based on data from six countries including Chile, an outlier. [71] . Pooled analysis of samples collected from India, Pakistan and Bhutan between 2007 and 2011 found that 76.9% (n = 65; 95% CI: 65.3-85.5%) were susceptible. Results were not stratified by country and, therefore, it is not known whether the sensitivity of isolates from India had changed [72] . Applying the more conservative breakpoint of >1 mg/ml to the in vitro studies identified in this review, 35% (7 of 20) of the in vitro studies reported upper range MICs that included gonococcal isolates resistant to azithromycin. This percentage does not include 16 studies we identified and included in TABLES 6 & 7 that did not report MICs.
Chlamydia trachomatis In vivo evidence
The WHO recommends treating pregnant women with Chlamydia trachomatis infection using 1 g azithromycin as a single oral dose [50] . We found eight RCTs in the literature that reported the treatment efficacy of 1 g azithromycin among pregnant women (TABLE 8 ) [73] [74] [75] [76] [77] [78] [79] [80] . Using random effect models, we estimate the pooled treatment efficacy to be 92.1% (n = 268; 95% CI: 88.4-95.7%). The estimated efficacy would be higher if we excluded two trials that were conducted in the USA. The first trial (1995-1997) reported a 3-week test of cure rate to be 88.1% (n = 42; 95% CI: 74.9-94.7%) [76] , whereas the second trial (1998-2000) was terminated early due to poor efficacy, 63.3% (n = 55; 95% CI: 50.4-75.1%), based on test of cure ‡4 weeks post-treatment [74] . These results need to be interpreted with caution because no distinction was made between treatment failures and new infections, sex partners were not treated by trial staff, but were referred to a treatment center, and only 35% of women were seen within 7 days of the scheduled test of cure.
Studies investigating sexual activity following treatment offer some perspectives on post-treatment infections and the extent to which they may be failures or de novo infections. A trial in Seattle (1998 Seattle ( -2003 found that persistent or recurrent chlamydial or gonorrheal infection occurred in 7.6% (n = 289; 95% CI: 5.1-4.9%) of female patients who reported no sexual intercourse after treatment [81] . Another study reported that 19.0% (n = 79; 95% CI 11.9-29.0%) of women were positive for C. trachomatis 3 months after treatment using 1 g azithromycin. Of these women, 13.3% (n = 15; 95% CI: 4.0-38.3%) reported being sexually inactive during the post-treatment period [82] . These findings may be attributable to false reporting of sexual contact, or treatment failure or may lend credence to the hypothesis that C. trachomatis enters a latent asymptomatic state that is undetectable by culture or, possibly, Nucleic Acid Amplification Tests, but can later reactivate [83] .
In vitro evidence
Thresholds for antimicrobial susceptibility and resistance of C. trachomatis are not universally standardized, although MICs >4 mg/ml are often used to characterize therapeutic failure [84] [85] [86] [87] . The lowest concentration of antimicrobial compound needed to inhibit chlamydial formation is between 0.03 and 0.125 mg/ml, whereas the minimum bactericidal concentration (MBC; also referred to as the minimum chlamydicidal concentration, or MCC) is between 0.06 and 0.5 mg/ml [88, 89] . The published in vitro studies of azithromycin collectively suggest the persistence of high and widespread treatment efficacy (TABLE 9) . One noted exception is the study of six isolates from three patients who experienced treatment failure in Russia (2000-2002) ; four isolates were resistant to azithromycin, doxycycline and ofloxacin at MICs and MBCs >5.12 mg/ml [90] . Not surprisingly, in vitro resistance appears to be more common in individuals with greater severity of disease or recurrent disease. A study in the USA during the early 1990s described decreased susceptibility and emerging resistance to azithromycin and doxycycline in isolates from women with mucopurulent cervicitis but not in isolates from women with asymptomatic infections [91] . Similar observations were reported in 2010 from India; six of eight isolates with modified susceptibility had been obtained from recurrently infected individuals, whereas the remaining two were from nonrecurrently infected patients. MICs and MBCs for azithromycin were 8 mg/ml for two of the patients from which the modified susceptibility isolates were taken. One individual had chronic cervicitis and the other had pelvic inflammatory disease [92] .
Trichomonas vaginalis In vivo evidence
Trichomonas vaginalis is a protozoal infection which causes cervicitis and nongonococcal urethritis. The WHO recommends treating pregnant women with T. vaginalis infection after the first trimester using 2 g metronidazole orally as a single dose, or 400-500 mg twice daily for 7 days or 300 mg clindamycin orally twice a day for 7 days [36] . If treatment is imperative during the first trimester of pregnancy, the single-dose regimen of 2 g metronidazole orally is recommended [36] . Azithromycin has not been used directly for prevention or treatment purposes because T. vaginalis is anaerobic. Nevertheless, azithromycin has demonstrated protection against T. vaginalis in studies of mass STI/RTI treatment (TABLES 10 & 11) .
In Kenya (1998-2002), 1 g azithromycin or placebo was given once per month to 466 HIV-negative female sex workers [93] . At the end of the trial, HIV incidence was the same across treatment groups, the primary endpoint, but the incidence of T. vaginalis was reduced significantly among those given azithromycin versus placebo (RR: 0.56; 96% CI: 0.40-0.78; p < 0.001). A similar observation was made in a threearm IPTp trial in Malawi (2003 Malawi ( -2006 [94] . Pregnant women received standard IPTp-SP, or monthly IPTp-SP or monthly IPTp-SP plus 1 g azithromycin during two antenatal visits; the prevalence of T. vaginalis at delivery was 16.7% (n = 411;
On the pathway to better birth outcomes? Review www.expert-reviews.com A cluster randomized trial in Uganda (1994-1998) compared the incidence of HIV infections among nonpregnant adults who received 1 g azithromycin, 250 mg ciprofloxacin and 2 g metronidazole versus multivitamins plus antihelminthics [95] . Although the trial was terminated early for lack of protection against the primary endpoint, the incidence of several curable STIs/RTIs was lower in the control group, most notably T. vaginalis. The same combination of antimicrobials was provided to female sex workers in rural Zimbabwe as a one-time treatment followed by 3 monthly check-ups [96] . The prevalence of T. vaginalis was just under 20% at baseline, decreased to approximately 5% at visit 2, rose to nearly 13% at visit 3 and lowered again to just over 10%, that is, one-half of the pretreatment levels.
Bacterial vaginosis
The WHO recommends treating bacterial vaginosis in pregnant women, preferably after the first trimester, with 200 or 250 mg metronidazole three-times per day for 7 days, or 5 g metronidazole gel (0.75%) applied intravaginally twice a day for 5 days or 300 mg clindamycin 300 mg orally twice a day for 7 days [36] . As with T. vaginalis, if treatment is imperative during the first trimester of pregnancy, 2 g metronidazole orally is recommended [36] . Bacterial vaginosis has no single causative agent, but is thought to result from destabilization of Lactobacillus species (spp.) with secondary colonization of anaerobic organisms that include Gardnerella vaginalis, Bacteroides spp, Mobiluncus spp. and Mycoplasma hominis alongside an increase in vaginal pH [97, 98] .
In vivo evidence Our review identified no trials that have attempted to measure the treatment efficacy of azithromycin alone against bacterial vaginosis. Only one study in the USA (2002) (2003) (2004) (2005) investigated the use of azithromycin as a partner drug with metronidazole for the treatment of symptomatic bacterial vaginosis. Nonpregnant women received one of four treatments: 750 mg metronidazole once per day for 7 days, or metronidazole once per day for 7 days plus 1 g azithromycin on days 1 and 3, or metronidazole for 14 days or metronidazole for 14 days plus azithromycin on days 1 and 3 [99] . No additional benefit of cure was observed among women who received metronidazole plus azithromycin compared with metronidazole alone.
Antibiotic treatment for bacterial vaginosis is challenging, in part, because it is a syndrome that involves multiple On the pathway to better birth outcomes?
Review www.expert-reviews.com Table 9 . Sensitivity testing of Chlamydia trachomatis isolates to azithromycin. Azithromycin and doxycycline bactericidal with MBC at one to two-times the MIC.
(50 strains) [188] Hong et al. azithromycin versus doxycycline (4 dilutions differences; 50 isolates) [84] Lefè vre et al. isolates from urethral and cervical samples (azithromycin 10 strains, doxycycline 22 strains, tetracycline 22 strains) [191] Scieux et al. 
>5.12
Isolates from salpingitis, endocervicitis, and urethritis showed resistance (6 isolates) [90] Somani et al.
USA 1995-1998 0.5 to >4.0 >4.0 Doxycycline: 0.125->4.0 >4.0 Resistance of strains causing relapsing or persistent infection in 3 patients (3 isolates) [193] Rice et al. Review Chico, Hack, Newport, Ngulube & Chandramohan Table 10 . Trials using azithromycin alone and in combination with other drugs reporting protection curable STIs/RTIs among pregnant women. include use of suboptimal syphilis treatment [196, 197] [ Low-risk populations † 2.4 mu benzathine Penicillin G was administered to pregnant women in all treatment groups per national guidelines (exception being [194] .
AZ: Azithromycin; CIPX: Ciprofloxacin; NR: Not reported; RR: Risk ratio; SP: Sulfadoxine-pyrimethamine.
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Review www.expert-reviews.com Table 11 . Trials using azithromycin alone and in combination with other antimicrobial therapies not contraindicated in pregnancy and reporting protection curable STIs/RTIs among commercial sex workers. Steen et al. 
Gardnerella vaginalis
Jones et al. Unspecified low-risk population. † Not a macrolide but has similar mechanism of action and included for comparability. NR: Not reported.
Review www.expert-reviews.com microorganisms rather than a single etiological agent. Comparable data from other macrolides suggest potential therapeutic value for azithromycin against bacterial vaginosis (TABLE 12) . Analysis of azithromycin against the anaerobic and carboxyphilic bacteria that replace the normal vaginal flora may provide a better understanding as to the potential role of azithromycin against bacterial vaginosis.
Discussion
Azithromycin has been used against curable STIs/RTIs for 25 years. It has been an attractive option for preventive and curative treatment because it is efficacious as a single dose and offers reasonable tolerability against T. pallidum, N. gonorrhoeae and C. trachomatis. During the 1990s, and prior to the advent of antiretroviral therapies for HIV, the management of curable STIs/RTIs received renewed importance, particularly as trials showed that treatment of N. gonorrhoeae, C. trachomatis and T. vaginalis reduced the genital viral load of HIV among men and women [100] [101] [102] [103] . Groups at high risk for transmitting HIV have since been targeted by treatment campaigns using 1 g azithromycin. Thus, it is not a surprise that changes in azithromycin sensitivity within high-income settings have often been observed first among members of high-risk groups. Pregnant women attending ANC facilities in sub-Saharan Africa do not have the same risk profile. Thus, on this basis alone, it is less likely that the use of ABC therapies in IPTp would be a catalyst for the rapid emergence of azithromycin resistance, although its emergence cannot be ruled out. The potential benefits of ABC therapies may be best viewed through prior experience with mass drug administration among pregnant women.
In the context of the AIDS epidemic and before the age of antiretroviral therapies, researchers attempted to prevent maternal-to-child transmission (MTCT) of HIV by providing pregnant women in Uganda 1 g azithromycin, in combination with 250 mg ciprofloxacin and 2 g metronidazole [104] . The data safety monitoring board suspended the trial early for reasons of futility, despite having cut neonatal deaths by 17% (RR: 0.83; 95% CI: 0.71-0.97), decreased the incidence of low birthweight by 32% (RR: 0.68; 95% CI: 0.53-0.86), and reduced the incidence of preterm delivery by 23% (RR: 0.77; 95% CI: 0.56-1.05). These impressive results were achieved at a time when neither IPTp-SP nor insecticide treated bed nets for the control of malaria in pregnancy had been deployed. If ABC therapies are used in IPTp, then there are several key factors to consider that are pathogen specific. Regarding syphilis, 1 g azithromycin should be used alongside 2.4 mu BPG for three reasons: combination therapy has been shown to achieve higher rates of cure than either therapy alone [105] ; use of ABC therapy with BPG would likely reduce selection of the A!G mutation associated with azithromycin and preserve T. pallidum sensitivity; and only BPG can be expected to cure congenital infection if the placenta has been invaded by spirochetes [106] . As for N. gonorrhoeae, 1 g azithromycin may be just above the MIC of fully susceptible strains. Thus, ABC therapies containing >1 g azithromycin may be preferable from the standpoint of reducing selection pressure. However, a single 2 g dose may not be well tolerated as 6 in 10 patients reported self-limiting gastrointestinal discomfort when treated for syphilis infection with such a regimen [42] . The dose could be split over 2 days to improve tolerability. ABC therapies that contain 2 g azithromycin, either a single-or split-dose, would be protective against C. trachomatis. Although the data are limited and the mechanism of action is not understood, ABC therapies that have 1 g azithromycin may protect against T. vaginalis based on reports from Malawi among pregnant women [107] and commercial sex workers in Kenya [93] . It is curious, however, that T. vaginalis infection during pregnancy is associated with adverse birth outcomes, but the first-line treatment of 2 g metronidazole does not always improve birth outcomes. A trial in Uganda reported that pregnant women treated for T. vaginalis infection were 2.5-times more likely to deliver a low birthweight infant than untreated women (RR: 2.49; 95% CI: 1.12-5.50) [108] . The authors suggest that this may be attributable to metronidazole exposure. Another trial in the USA reported an increase in the risk of preterm delivery among pregnant women exposed to metronidazole for the treatment of asymptomatic trichomoniasis compared with those who were not treated (RR: 1.8; 95% CI: 1.2-2.7) [109] . In contrast to these findings from high-income settings, data from a multicenter trial in subSaharan Africa indicate that treatment of T. vaginalis infection using metronidazole does not increase the chances of preterm birth [110] . Apart from bacterial vaginosis, which is not transmitted through sexual contact, re-infection will remain a risk for pregnant women and, therefore, providers should continue to offer education and screening as appropriate.
None of the studies identified in this review indicate that azithromycin offers preventive or curative effect against bacterial vaginosis, the most prevalent of curable STIs/RTIs. Antibiotic therapy has only been shown to reduce the risk of preterm delivery by one-half (RR: 0.53; 95% CI: 0.34-0.84) among pregnant women with bacterial vaginosis (Nugent scores 7-10) or intermediate flora [111] . A Nugent score of 0-3 is considered normal [112] for which no protection against adverse birth outcomes has been observed.
Conclusions
ABC therapies are among leading candidates to replace SP for use in IPTp and may offer important public health benefits by also reducing the burden of curable STIs/RTIs in pregnancy. Evidence from nonpregnant adults suggests that ABC therapies containing 1 g azithromycin may cure maternal T. pallidum infection. BPG should still be administered with azithromycin because the combination has been shown to be more efficacious in nonpregnant adults than either treatment alone. Moreover, evidence from pregnant women indicates that eradication of congenital syphilis may require BPG treatment. Neisseria gonorrhoeae infection among pregnant women in sub-Saharan Africa, where strains are likely to be fully sensitive to azithromycin, is likely to be cured by ABC therapies containing 1 g azithromycin. However, 2 g may be needed to reduce persistent and/or recurrent infection, and opportunities for the emergence of drug resistance. ABC therapy containing 1 g azithromycin would be curative of C. trachomatis infection, whereas some protection against T. vaginalis infection could be expected with the same dose. It remains unknown whether ABC therapies could offer protection against bacterial vaginosis if administered during the first half of pregnancy. ABC therapies merit investigation for the use in IPTp given their potential to reduce the dual burden of malaria and curable STIs/RTIs in pregnancy and improve maternal, fetal and neonatal health.
Expert commentary
Current strategies for addressing the dual-burden of malaria and curable STIs/RTIs in pregnancy are suboptimal. In West Africa, IPTp-SP continues to provide protection against the effects of malaria infection but, as previously noted, malaria parasites in East Africa have developed resistance so that IPTp-SP no longer protects against the malaria attributable fraction of low birthweight [3] . Some evidence suggests that IPTp-SP may even be harmful in areas where parasites express the 581G dhps mutation [4] [5] [6] . ABC therapies are likely to be more efficacious against malaria parasites in these settings. However, there is an urgent need for trials of ABC therapies to be conducted by independent researchers for policymakers to review alongside the results of trials produced and reported by industry.
In the case of curable STIs/RTIs, the focused ANC package recommended by the WHO includes screening for syphilis and the provision of BPG to women who test positive [50] . Screening would need to continue even if ABC therapies were used in IPTp. The WHO currently recommends the use of rapid point of care tests for syphilis in the ANC setting [113] . Using such tests will expedite case finding and treatment with BPG because results are available during the same consultation. As for the four other curable STIs/RTIs of this review, health care providers are limited to the use of a syndrome-based management algorithm to diagnose and to treat suspected infections. However, 80% of gonococcal and 70-75% chlamydial infections in women are asymptomatic [114] and, therefore, rarely recognized using the syndromic approach. As a result, the diagnostic algorithm has a low sensitivity (30-80%) and specificity (40-80%) for N. gonorrhoeae and C. trachomatis among pregnant women [115] [116] [117] . The sensitivity for T. vaginalis (54-83%) and bacterial vaginosis (51-69%) is slightly higher, with moderate specificity for T. vaginalis (40-54%) and bacterial vaginosis (40-58%) [118] . Given the evidence of this review, ABC therapies used in IPTp could be expected to mitigate a considerable proportion of this unattended burden of curable STIs/RTIs.
Much is debated about the utility of a syndrome-based approach to diagnosing and treating many STIs/RTIs. Its shortcomings, as described above, illuminate a much-needed area for research. Specifically, more refined definitions of diagnosis need to be used when characterizing adverse birth outcomes. This is particularly so with T. vaginalis for which successful treatment does not necessarily reduce the risk of adverse birth outcomes. Similarly with bacterial vaginosis, treatment of women who have Nugent scores of 1-3 has not reduced the incidence of preterm birth. With both of these infections, is the recommended regimen of metronidazole inadequate for radical cure? Is it administered too late in pregnancy to alter the course of events? Or are asymptomatic infections simply much less virulent and, therefore, treatment has a marginal effect on selected downstream measures of the adverse birth outcome? Studies of descriptive epidemiology are needed to understand better the extent to which symptomatic versus asymptomatic curable STIs/RTIs contribute to adverse birth outcomes. Such descriptive epidemiology, however, would be incomplete if the prevalence of co-infections were not also considered. The apparent failure to reduce the incidence of adverse birth outcomes following treatment for one infection may be masked by the presence of co-infection(s) that will only be mitigated with the use of combination therapies and consideration of downstream outcomes. The trial in Uganda that failed to reduce the incidence of MTCT of HIV is illustrative. HIV transmission was not interrupted for providing combination treatment against curable STIs/RTIs, but significant reductions were observed in the incidence of neonatal deaths by 17% (RR: 0.83; 95% CI: 0.71-0.97) and low birthweight by 32% (RR: 0.68; 95% CI: 0.53-0.86) [104] .
Five-year view
Discussion of the future of IPTp needs to be placed in the context of broader malaria elimination efforts. IPTp-SP has long been considered a malaria control intervention that can be expected to protect less against the fraction of low birthweight attributable to malaria infection as malaria transmission decreases. Recent evidence suggests that IPTp-SP continues to protect against low birthweight among multigravidae in areas where the prevalence of malaria parasitemia measured in children is between 7 and 8%, whereas protection is conferred by IPTp-SP among paucigravidae until very low levels of transmission [119] . Unpublished results from a recently completed multicenter trial in West Africa, where there remain malaria parasites sensitive to SP, indicate that an approach of intermittent screening and treatment (IST) of malaria in pregnancy is noninferior to IPTp-SP (Manuscript under review/personal communication with D. Chandramohan). Thus, there is an urgent need for clinical trials in an area of high SP resistance in East Africa, designed to compare ABC therapies versus IST versus IPTp-SP. ABC therapies, given their action against malaria and curable STIs/RTIs, would be superior to IST and IST would be superior to IPTp-SP, potentially paving the way for adoption of an integrated malaria and curable STI/RTI control package that employs the use of combination treatment.
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Key issues
• Use of azithromycin-based combination (ABC) therapies may have a transformative effect on maternal, fetal and newborn heath by mitigating the dual-burden of malaria and curable sexually transmitted infections and reproductive tract infections sexually transmitted infections and reproductive tract infections (STIs/RTIs) in pregnancy.
• ABC therapies containing two or more grams of azithromycin may be less likely to select for resistance when exposed to Treponema pallidum, Neisseria gonorrhoeae and potentially, Chlamydia trachomatis.
• In the absence of evidence that azithromycin is curative of congenital syphilis, not simply maternal infection, benzanthine penicillin G (BPG) will still need to be administered to pregnant women who have a syphilis infection; however, the combination of azithromycin plus BPG is more efficacious that BPG alone.
• ABC therapies may be preventive of Treponema vaginalis infection during pregnancy, although its impact on birth outcomes needs to be investigated.
• The most prevalent of all STIs/RTIs, bacterial vaginosis, may or may not be mitigated by the use of ABC therapies.
• Studies of descriptive epidemiology are needed to understand better the extent to which symptomatic versus asymptomatic curable STIs/ RTIs contribute to adverse birth outcomes. There is an urgent need for clinical trials in an area of high sulfadoxine-pyrimethamine resistance in East Africa, designed to compare ABC therapies versus IPTp-SP versus providing IST for malaria in pregnancy during ANC visits. Review www.expert-reviews.com
